NASDAQ:MENS - KYG831161065 - Common Stock
The current stock price of MENS is 59.8 USD. In the past month the price increased by 154.9%.
Symbol | Company Name | TA | FA | PE | Market Cap |
---|---|---|---|---|---|
ABBV | ABBVIE INC | 20.01 | 374.37B | ||
AMGN | AMGEN INC | 13.16 | 154.47B | ||
GILD | GILEAD SCIENCES INC | 14.56 | 139.85B | ||
VRTX | VERTEX PHARMACEUTICALS INC | 23.67 | 102.81B | ||
REGN | REGENERON PHARMACEUTICALS | 12.66 | 61.25B | ||
ALNY | ALNYLAM PHARMACEUTICALS INC | N/A | 58.59B | ||
ARGX | ARGENX SE - ADR | 76.2 | 43.23B | ||
ONC | BEONE MEDICINES LTD-ADR | 6.69 | 39.47B | ||
INSM | INSMED INC | N/A | 30.71B | ||
BNTX | BIONTECH SE-ADR | N/A | 24.19B | ||
NTRA | NATERA INC | N/A | 23.24B | ||
BIIB | BIOGEN INC | 8.72 | 20.47B |
Jyong Biotech Ltd. operates as a holding company, which engages in the development of biotechnology products. The company is headquartered in Taipei, New Taipei and currently employs 29 full-time employees. The company went IPO on 2025-06-17. The firm is mainly engaged in developing and commercializing innovative and differentiated new drugs (plant-derived) mainly specializing in the treatment of urinary system diseases, with an initial focus on the markets of the United States (U.S.), the European Union (EU), and Asia. The firm has been developing a series of botanical drug candidates, including primary botanical drug candidate of MCS-2, another clinical-stage botanical drug candidate of PCP, and other preclinical-stage botanical drug candidates. MCS-2 is a new botanical drug candidate developed for treatment of benign prostate hyperplasia/lower urinary tract symptoms (BPH/LUTS). PCP is a new botanical drug candidate developed for the prevention of prostate cancer.
JYONG BIOTECH LTD
23F-3, No.95, Section 1, Xintai 5th, Xizhi District
Taipei NEW TAIPEI TW
Employees: 29
Phone: 886227325205
The current stock price of MENS is 59.8 USD. The price increased by 9.1% in the last trading session.
The exchange symbol of JYONG BIOTECH LTD is MENS and it is listed on the Nasdaq exchange.
MENS stock is listed on the Nasdaq exchange.
JYONG BIOTECH LTD (MENS) has a market capitalization of 4.55B USD. This makes MENS a Mid Cap stock.
JYONG BIOTECH LTD (MENS) currently has 29 employees.
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
MENS does not pay a dividend.
JYONG BIOTECH LTD (MENS) does not have a PE ratio as the earnings reported over the last twelve months were negative (-0.04).
The outstanding short interest for JYONG BIOTECH LTD (MENS) is 0.5% of its float. Check the ownership tab for more information on the MENS short interest.
ChartMill assigns a technical rating of 5 / 10 to MENS.
ChartMill assigns a fundamental rating of 1 / 10 to MENS. MENS may be in some trouble as it scores bad on both profitability and health.
Over the last trailing twelve months MENS reported a non-GAAP Earnings per Share(EPS) of -0.04. The EPS increased by 31.43% compared to the year before.
Industry Rank | Sector Rank | ||
---|---|---|---|
PM (TTM) | N/A | ||
ROA | -47.42% | ||
ROE | N/A | ||
Debt/Equity | N/A |